Dr. Luke is the Director of the Immunotherapy and Drug Development Center at UPMC Hillman Cancer Center and Associate Professor at the University of Pittsburgh. He focuses on translational therapeutic advances in immuno-oncology, early phase drug development for advanced solid tumors and the management of patients with cutaneous malignancies. In melanoma, Dr. Luke has designed and led two practice changing studies documenting the role of combination anti-PD1 + low dose anti-CTLA4 Ab in PD1 refractory disease as well as establishing the role for, and FDA/EMA approval of, adjuvant anti-PD1 for stage IIB/C melanoma. 

More generally, Dr Luke has been a lead investigator for clinical trials of many first-in-human novel immunotherapies in advanced solid tumors. He has been a major contributor toward the investigation of radiation and the microbiome in relation to cancer immunotherapy. His translational research laboratory focuses on biomedical and bioinformatic approaches to advance cancer immunotherapy. 

Dr Luke is an At Large member of the Board of Directors for SITC and has held leadership roles in SMR, AACR & ASCO. He is a member of the NCI Investigational Drug Steering Committee and the Immunotherapy Task Force co-Chair. Dr Luke is the PI or Project leader for multiple funding mechanisms including R01, UM1, P50 & multiple state or private grants.